DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vs5rnv/research_report) has announced the addition of the "Research Report on Global and China In-Vitro Diagnostic Reagent Industry, 2013-2017" report to their offering.
In Chinese market, there are mainly three categories of in-vitro diagnostic reagents, biochemical diagnostic reagents, immune diagnostic reagents and molecular diagnostic reagents, accounting for about 65% of in-vitro diagnostic reagent market in total in 2012.
Global in-vitro diagnostics market is mature and the concentration rate is high. The 8 major enterprises account for over 70% market share. In 2011, the market scale of global in-vitro diagnostics reached USD 46 billion, among which developed countries accounted for over 80%. Currently, emerging economic entities occupy low proportions, while their growth rates are far ahead of that of mature markets.
In China, barriers to entry of this industry are not high and the concentration rate is low. The majority of enterprises concentrate in the biochemical reagent field, so the competition is mainly in the biochemical field. Both the supply and demand of immune and molecular products are prosperous. In addition to immune reagents, markets of other diagnostic reagents are mainly occupied by Chinese domestic enterprises. Although China in-vitro diagnostic reagent industry started late and its scale is limited, it grows rapidly. In 2012, the market scale reached CNY 13.6 billion, among which immune diagnostic reagents, biochemical diagnostic reagents and molecular diagnostic reagents ranked among the top.
China's population accounts for more than 20% of the world's population, while the market share of in-vitro diagnostics is less than 5% of the world's; in 2012, the annual consumption per capita of China's in-vitro diagnostic products was less than USD 2, while that of developed countries reached USD 25 to USD 30. Therefore, there is a wide growth space for China's in-vitro diagnostics. CRI predicts that the growth rate of the market scale of China's in-vitro diagnostics will be markedly higher than the global average level and the CAGR will maintain over 15% from 2013 to 2017. By 2017, the market scale will reach CNY 30 billion, among which immune and biochemical products will continually occupy most of the market share, while the proportion of molecular products will relatively increase. During the upgrading of products in the future and the process of domestic substitution, the industry concentration rate will grow.
Readers can obtain the following information or more through this report:
- Status of Global and China In-vitro Diagnostic Reagents
- Governmental Policies on China In-vitro Diagnostic Reagent Industry
- Status of Market Competition in In-vitro Diagnostic Reagent Industry
- Major In-vitro Diagnostic Reagent Manufacturers in Global and China Markets
- Forecast on the Development of In-vitro Diagnostic Reagent Industry
Key Topics Covered:
Chapter 1 Overview on In-vitro Diagnostic Reagent Industry
Chapter 2 Global In-vitro Diagnostic Reagent Industry, 2011-2013
Chapter 3 Development Environment of China In-vitro Diagnostic Reagent Industry, 2011-2013
Chapter 4 Operation Status of China Diagnostic Reagent Industry, 2008-2012
Chapter 5 Top 5 Enterprises of China's In-vitro Diagnostic Reagent Industry, 2011-2013
Chapter 6 Prospect of China In-vitro Diagnostic Reagent Industry, 2013-2017
- Beijing Leadman Biochemistry Co., Ltd.
- BioSino Bio-technology and Science Inc.
- DAAN Gene Co., Ltd. of Sun Yat-sen University
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Shanghai Kehua Bio-engineering Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/vs5rnv/research_report